title: Failure of estrogen to protect the substantia nigra pars compacta of female rats from lesion induced by 6-hydroxydopamine.
abstract: The immunostaining for tyrosine hydroxylase (TH) in the substantia nigra pars compacta (SNpc) and in the ventral tegmental area (VTA) after intranigral infusion of 6-hydroxydopamine (6-OHDA, 6 microg/side) was analyzed in ovariectomized adult female Wistar rats. Estrogen replacement for 52 days (400-microg 17-beta-estradiol capsules) did not prevent the loss of TH-immunoreactive cells induced by 6-OHDA in the SNpc. This result indicates that the neuroprotective effect of dopaminergic mesencephalic cells is not observed with long-term estrogen replacement.
authors.affiliation: Laboratório de Fisiologia e Farmacologia do Sistema Nervoso Central, Departamento de Fisiologia e Farmacologia, Universidade Federal do Paraná, CP 19.031, 81.531-990 Curitiba, PR, Brazil. anete@ufpr.br
authors.forename: Anete Curte
authors.initials: AC
authors.lastname: Ferraz
authors.forename: Léder Leal
authors.initials: LL
authors.lastname: Xavier
authors.forename: Sílvia
authors.initials: S
authors.lastname: Hernandes
authors.forename: Martha
authors.initials: M
authors.lastname: Sulzbach
authors.forename: Giordano Gubert
authors.initials: GG
authors.lastname: Viola
authors.forename: Janete A
authors.initials: JA
authors.lastname: Anselmo-Franci
authors.forename: Matilde
authors.initials: M
authors.lastname: Achaval
authors.forename: Claudio
authors.initials: C
authors.lastname: Da Cunha
mesh_terms: D000818:Animals; D004298:Dopamine / Q000378:metabolism; D004967:Estrogens / Q000494:pharmacology*; D005260:Female; D009474:Neurons / Q000187:drug effects* / Q000378:metabolism; D018696:Neuroprotective Agents / Q000494:pharmacology*; D016627:Oxidopamine / Q000494:pharmacology; D020734:Parkinsonian Disorders / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D051381:Rats; D017208:Rats, Wistar; D013378:Substantia Nigra / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology; D017211:Treatment Failure; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism; D017557:Ventral Tegmental Area / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology
chemical_list: D004967:Estrogens; D018696:Neuroprotective Agents; D016627:Oxidopamine; D014446:Tyrosine 3-Monooxygenase; D004298:Dopamine